Bayer’s Finerenone Shows Renal, CV Benefits In CKD/Type 2 Diabetes Patients – But Is It Enough?

 
• By Joseph Haas
  
Kidney
Bayer plans to file finerenone for reduction of renal, CV outcomes risk
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D